Autoimmune Diseases  >>  tregalizumab (BT-061)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tregalizumab (BT-061) / ADMA Biologics, T-Balance Therapeutics
NCT01999192: Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

Checkmark ACR responses at week 12 and week 24
Nov 2015 - Nov 2015: ACR responses at week 12 and week 24
Terminated
2b
321
US, Canada, Europe, RoW
Tregalizumab, BT061, Placebo
Biotest, AbbVie
Rheumatoid Arthritis
07/15
07/15
NCT01072383 / 2008-007458-37: Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Checkmark Data
Nov 2011 - Nov 2011: Data
Completed
2
49
Europe
BT061, SC or IV administration of BT061 or placebo, placebo treatment
Biotest
Psoriasis Vulgaris
06/11
08/11
NCT01481493 / 2010-018485-24: Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Checkmark For rheumatoid arthritis at ACR 2013
Oct 2013 - Oct 2013: For rheumatoid arthritis at ACR 2013
Checkmark Rheumatoid arthritis - ACR/ ARHP 2013
Sep 2013 - Sep 2013: Rheumatoid arthritis - ACR/ ARHP 2013
Completed
2
127
Europe
BT061, immune-modulatory antibody BT061, Placebo, end formulation buffer without active ingredient
Biotest
Rheumatoid Arthritis
08/13
11/13

Download Options